Parexel CEO to retire; CAR-T maker AffyImmune promotes business leader to chief executive

Peyton Howell

Jamie Macdonald will retire as CEO of Parexel on May 15, and the clinical research organization has already named Peyton Howell — the current chief operating and growth officer — as his successor. Macdonald replaced co-founder and longtime chief executive Josef von Rickenbach in March 2018, and Howell arrived two months later as chief commercial and strategy officer. Earlier, she handled a series of roles for more than a decade at AmerisourceBergen.

“Jamie guided Parexel through a pivotal time in the company’s evolution, leading it through its successful acquisition by EQT and Goldman Sachs Asset Management in 2021 and achieving industry-leading profit growth across his tenure with the company — outpacing the top-tier CROs during this same period to position Parexel for sustainable growth,” board chair Sheri McCoy said in a statement.

Macdonald will keep…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks